Fig. 7: LXN deficiency in hematopoietic lineage exacerbates tumorigenesis in vivo.

A Schematic representation of mouse model of bone marrow transplantation. Bone marrow transfers were performed in 6-weeks old lethally irradiated WT mice (CD45.1 background) followed by reconstitution with bone marrow from WT or LXN KO mice (CD45.2 background), respectively. Then, four cycles of AOM/DSS treatment to induce colorectal cancer. B Representative FACS plots show CD45.2⁺ and CD45.1⁺ cells in the peripheral blood of donor mice and recipient mice before and after bone marrow transplantation, respectively. C Survival of AOM/DSS-treated mice (CD45.1 background) after conducted transplantation with WT and LXN KO bone marrow (CD45.2 background) (n = 18 mice per group). D Representative images of colorectal tissue of each group chimeras and tumor number and size were counted. n = 6, **P < 0.01, ***P < 0.001. E Representative images of cross-sections of the tumor tissues from each group stained with anti-PD-L2 antibody. Quantification of PD-L2 positive cells are shown. Scale bars = 100 µm. n = 6, **P < 0.01. F, G Frequencies of WT or LXN KO donor (CD45.2)-derived F4/80⁺PD-L2⁺ cells (F), CD3⁺, CD3⁺CD8⁺ and CD3⁺CD4⁺ T cells (G) in the tumor of recipient mice (CD45.1) after 4 cycles of AOM/DSS treatment. n = 6, *P < 0.05, **P < 0.01, ***P < 0.001. Data are representative of three independent experiments.